Last reviewed · How we verify
CINRYZE 1000
CINRYZE is a plasma kallikrein inhibitor that reduces bradykinin production to prevent acute attacks in hereditary angioedema.
CINRYZE is a plasma kallikrein inhibitor that reduces bradykinin production to prevent acute attacks in hereditary angioedema. Used for Hereditary angioedema (HAE) — acute attack prevention and treatment.
At a glance
| Generic name | CINRYZE 1000 |
|---|---|
| Sponsor | Shire |
| Drug class | C1 esterase inhibitor (plasma-derived) |
| Target | Plasma kallikrein; C1 esterase inhibitor |
| Modality | Biologic |
| Therapeutic area | Immunology / Rare Disease |
| Phase | Phase 3 |
Mechanism of action
CINRYZE (C1 esterase inhibitor [human]) works by inhibiting plasma kallikrein, a key enzyme in the contact system that generates bradykinin, a potent inflammatory mediator. By reducing bradykinin production, the drug prevents the vasodilation and increased vascular permeability that characterize acute angioedema attacks in patients with hereditary angioedema (HAE). This mechanism addresses the underlying pathophysiology of HAE rather than just treating acute symptoms.
Approved indications
- Hereditary angioedema (HAE) — acute attack prevention and treatment
Common side effects
- Thrombosis / thromboembolic events
- Hypersensitivity reactions
- Headache
- Nausea
Key clinical trials
- Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study). (PHASE2)
- A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase (PHASE2)
- Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema (PHASE3)
- CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 (PHASE2)
- Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) (PHASE3)
- C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation (PHASE1)
- C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation (PHASE4)
- Berinert P Study of Subcutaneous Versus Intravenous Administration (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CINRYZE 1000 CI brief — competitive landscape report
- CINRYZE 1000 updates RSS · CI watch RSS
- Shire portfolio CI